Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know

2026-10-05
Quest Diagnostics is set to report its Q3 earnings next month, with analysts expecting single-digit year-over-year EPS growth.

Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus

2026-10-05
TMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.

Dividend Champion, Contender, And Challenger Highlights: Week October 4

2026-10-02
Track weekly dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates. Read it here.

Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8

2026-10-02
Quest Diagnostics (DGX) scores 7 for trend and 8 for setup, with a defined breakout entry above 237.95 and support near 230.87.

Apple Is Betting Improved Heart and Health Insights Will Boost Watch Sales

2026-10-01
Like runners striving to break from the pack, a slew of wearables companies are competing for share of consumers’ health and fitness tracking habits. With Apple latest heart-rate focused updates to its best-selling Apple Watch and an upcoming Health app redesign, it’s hoping to expand an already impressive lead. Users will be able to calculate their “health age”—a comparison of their overall health measurements with their actual age—as well as a Readiness score that gauges capacity for strenuous activity.

Apple’s Betting Improved Heart and Health Insights Will Boost Watch Sales

2026-10-01
Like runners striving to break from the pack, a slew of wearables companies are competing for share of consumers’ health and fitness tracking habits. With Apple latest heart-rate focused updates to its best-selling Apple Watch and an upcoming Health app redesign, it’s hoping to expand an already impressive lead. Users will be able to calculate their “health age”—a comparison of their overall health measurements with their actual age—as well as a Readiness score that gauges capacity for strenuous activity.

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

2026-10-01
A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series. The study also validated the test’s analytical performance across 23 solid tumor types. Provided by Quest Diagnostics (NYSE: DGX), Haystack MRD is an ultrasensitive circulating tumor DNA (ctDNA) liquid biopsy test for identifying res

Who We Play For and Myelai Launch Heart Screening Program at Quest Diagnostics in Tampa as Florida Becomes First State to Require ECGs for High School Athletes

2026-09-30
Who We Play For, a nonprofit that championed Florida's Second Chance Act, Myelai, and Unless Health today announce the launch of a cardiac screening program at Quest Diagnostics' Sheldon Road location in Tampa, giving families a fast way to complete the electrocardiogram (ECG) heart screening now required for Florida high school athletes.

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

2026-09-25
DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.

Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch

2026-09-23
Quest Diagnostics (DGX) drew fresh attention after announcing an Apple Health integration that allows iPhone and iPad users to order a preventive lab panel with more than 50 biomarkers for US$119. The Apple Health tie-in lands after a strong run in Quest Diagnostics’ shares, with the price up 15.6% over 90 days and 35.1% year to date, even though the last month’s share price return slipped 3.9% as traders reassessed shorter term risk and reward. Scan beyond Quest Diagnostics and see how other...